22.72
-0.6(-2.57%)
Currency In USD
| Previous Close | 23.32 |
| Open | 23.16 |
| Day High | 23.49 |
| Day Low | 22.56 |
| 52-Week High | 28.49 |
| 52-Week Low | 9.03 |
| Volume | 533,499 |
| Average Volume | 913,348 |
| Market Cap | 1.7B |
| PE | -26.73 |
| EPS | -0.85 |
| Moving Average 50 Days | 24.58 |
| Moving Average 200 Days | 17.62 |
| Change | -0.6 |
If you invested $1000 in Zymeworks Inc. (ZYME) since IPO date, it would be worth $1,747.69 as of February 21, 2026 at a share price of $22.72. Whereas If you bought $1000 worth of Zymeworks Inc. (ZYME) shares 5 years ago, it would be worth $560.85 as of February 21, 2026 at a share price of $22.72.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026
GlobeNewswire Inc.
Feb 12, 2026 11:00 AM GMT
VANCOUVER, British Columbia, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline of novel, multifunctional biotherapeutics,
Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy
GlobeNewswire Inc.
Jan 12, 2026 11:00 AM GMT
Investment industry veteran Mr. Brian Cherry appointed to Board of DirectorsDr. Sabeen Mekan to transition to Chief Medical Officer effective February 1, 2026 and Mark Hollywood promoted to Executive Vice President and Chief Operating OfficerFive new
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit
GlobeNewswire Inc.
Jan 06, 2026 6:34 PM GMT
Positive results from Phase 3 HERIZON-GEA-01 results support Ziihera as the HER2-targeted agent-of-choice in HER2+ first-line metastatic GEA and Ziihera plus chemotherapy to replace trastuzumab as the new standard of care, with or without tislelizuma